<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="[!info]
🌱 來自: [[Huppert&rsquo;s Notes]]
 Other Rheumatologic Conditions #🚧 施工中 Other Rheumatologic Conditions Polymyalgia rheumatica (PMR) • Clinical features:"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Other Rheumatologic Conditions"><title>Other Rheumatologic Conditions</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.547fb332ce56cdc523146ba5ede80d7f.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.778468a19a5f9b81b42c7351e4628fc2.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.3d40c954c7957050e451e70a51aedbd1.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Other Rheumatologic Conditions</h1><p class=meta>最後更新於
Jan 22, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Other%20Rheumatologic%20Conditions.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><blockquote class=info-callout><p></p><p>🌱 來自: <a class="internal-link broken">Huppert&rsquo;s Notes</a></p></blockquote><a href=#other-rheumatologic-conditions--施工中><h1 id=other-rheumatologic-conditions--施工中><span class=hanchor arialabel=Anchor># </span>Other Rheumatologic Conditions #🚧 施工中</h1></a><a href=#other-rheumatologic-conditions><h3 id=other-rheumatologic-conditions><span class=hanchor arialabel=Anchor># </span>Other Rheumatologic Conditions</h3></a><a href=#polymyalgia-rheumatica-pmr><h5 id=polymyalgia-rheumatica-pmr><span class=hanchor arialabel=Anchor># </span>Polymyalgia rheumatica (PMR)</h5></a><p>•   Clinical features:</p><p>-   Syndrome of neck, shoulder, and hip girdle stiffness that is typically worse after immobility; associated with elevations in markers of systemic inflammation (e.g., ESR, CRP)</p><p>-   50% of patients with GCA have PMR, and 20% of patients with PMR have GCA</p><p>•   Diagnosis:</p><p>-   A diagnosis of exclusion made after ruling out myopathies (for myopathy, weakness > pain; for PMR, pain > weakness) or non-systemic periarticular syndromes, such as adhesive capsulitis</p><p>-   May be difficult to distinguish from seronegative RA as some patients have a distal polyarthritis; when present, erosive disease favors a diagnosis of RA</p><p>-   Improves briskly with prednisone 12.5–20 mg daily and failure to improve as expected with steroids should raise suspicion for the presence of an alternative diagnosis</p><p>•   Treatment: Prednisone 20 mg/day and prolonged taper (often 1–2 yr)</p><a href=#behçet-syndrome><h5 id=behçet-syndrome><span class=hanchor arialabel=Anchor># </span>Behçet syndrome</h5></a><p>•   Pathogenesis: Not fully elucidated; increased risk with HLA-B51 allele implicates cell-mediated autoimmunity (US cases tend not to be associated with this HLA type)</p><p>•   Epidemiology: Incidence 1/100,000 individuals annually in the United States; 400/100,000 individuals annually in Turkey. Also relatively more prevalent in Iran, Saudi Arabia, Greece, Japan, Korea, and China, tracking with the distribution of the HLA-B51 allele. Age of onset typically 20–30 yr.</p><p>•   Clinical features:</p><p>-   <strong>Derm</strong>: Recurrent genital and oral ulcers (the latter occur in nearly 100% of patients and are painful, unlike those that occur in SLE); erythema nodosum with ulceration; pseudofolliculitis/nodular cystic acne of the face and neck</p><p>-   <strong>Vascular</strong>: Vasculitis with potential small (retinal), medium (mesenteric) and large (pulmonary, carotid, aortic, iliac, femoral) vessel involvement; venous and arterial thrombi (potentially IVC thrombosis, dural venous sinus thrombosis, arterial thromboses, and aneurysms)</p><p>-   <strong>GI</strong>: Apthous ulcers of the ileum/cecum presenting with abdominal pain, anorexia, diarrhea, GI bleeding</p><p>-   <strong>Articular</strong>: Inflammatory oligoarthritis in ~50% of patients with large joint-predominance (knees most common); sacroiliitis</p><p>-   <strong>Ocular</strong>: Uveitis (anterior, posterior, or panuveitis); retinal vasculitis</p><p>-   <strong>CNS</strong>: Headache, altered mental status; CSF may show elevated protein and leukocytosis; cranial neuropathies including CN VIII</p><p>•   Diagnosis: See Table 9.11</p><p><strong>TABLE 9.11</strong> • International Criteria for Behçet’s Disease</p><p>-   <strong>Pathergy</strong>: A skin prick is performed with a sterile needle, and the site is assessed 48 hr later. Patients who develop a pustule are deemed to have a positive test.</p><p>-   <strong>DDx for recurrent oral ulcers:</strong> HSV, HIV, Crohn’s, nutritional deficiency (iron, zinc, folate, B1, B2, B6, B12), cyclic neutropenia, reactive arthritis, methotrexate</p><p>•   Treatment:</p><p>-   Oral and genital ulcers: Topical glucocorticoids for management of active lesions; colchicine for prevention of new genital lesions and erythema nodosum</p><p>-   Arthritis: Colchicine for acute flares; azathioprine or TNFα inhibitors for chronic arthritis</p><p>-   Thrombotic events: Anticoagulation, also consider immunosuppression with glucocorticoids</p><p>-   Intestinal ulcer flares: High-dose glucocorticoids (1 mg/kg) with subsequent mesalamine or azathioprine</p><p>-   CNS disease: High-dose glucocorticoids (1 mg/kg) with subsequent introduction of azathioprine</p><a href=#relapsing-polychondritis><h5 id=relapsing-polychondritis><span class=hanchor arialabel=Anchor># </span>Relapsing polychondritis</h5></a><p>•   Pathogenesis: Not fully elucidated; involves episodic immune-mediated damage to cartilaginous tissues including the ears, nose, and proximal tracheobronchial tree</p><p>•   Epidemiology: Incidence 3.5/million individuals annually, mean age at diagnosis 47 yr</p><p>•   Disease categories:</p><p>-   Primary: No evidence of a separate underlying rheumatic or hematologic disease</p><p>-   Secondary (30%): Occurring in the context of GPA, RA, SLE, or myelodysplastic syndrome</p><p>•   Clinical features:</p><p>-   <strong>Inflammation of cartilaginous tissues:</strong> Auricular chondritis (red/tender cartilaginous ear with sparing of the lobe, 90% patients), nasal cartilage inflammation which can cause septal perforation and saddle nose deformity</p><p>-   <strong>Articular manifestations:</strong> Episodic, migratory inflammatory oligoarthritis in ~70% patients, occurring contemporaneously with inflammation at other cartilaginous sites</p><p>-   <strong>Airway disease:</strong> Subglottic tracheal stenosis; bronchiectasis</p><p>•   Diagnosis:</p><p>-   Clinical diagnosis typically made on the basis of auricular chondritis, saddle nose deformity, tracheobronchial involvement, and exclusion of other conditions</p><p>-   If atypical manifestations, auricular cartilage biopsy during flare reveals perichondrium inflammatory cell infiltration</p><p>•   Differential diagnosis:</p><p>-   Ddx for auricular erythema: Otitis externa/auricular cellulitis</p><p>-   Ddx for nasal inflammation/saddle nose deformity: GPA, Crohn’s, NK cell lymphoma, syphilis, leprosy, leishmaniasis</p><p>•   Treatment:</p><p>-   Flares of cartilaginous inflammation (auricular or nasal chondritis): Glucocorticoids first-line</p><p>-   Tracheobronchial disease: Local glucocorticoid injections, stents for stenotic areas, CPAP</p><a href=#igg4-related-disease><h5 id=igg4-related-disease><span class=hanchor arialabel=Anchor># </span>IgG4-related disease</h5></a><p>•   Pathogenesis: Not fully elucidated, but involves tissue infiltration with IgG4 plasma cells as well as copious lymphocytes, eosinophils, and dense fibrosis</p><p>•   Epidemiology: Prevalence not yet described; M:F = ~3:1 for IgG4-related pancreatitis</p><p>•   Clinical features:</p><p>-   <strong>General patterns of disease:</strong> Tumefactive fibrotic organ infiltration with predominant involvement of exocrine organs. Preceding atopic disease is common but typically less active</p><p>-   <strong>Ocular:</strong> “Orbital apex syndrome”/orbital pseudotumor causing proptosis</p><p>-   <strong>Exocrine glands:</strong> Autoimmune pancreatitis (presenting with abdominal pain and/or obstructive jaundice; serum IgG4 is often elevated but a biopsy is typically needed to rule out malignancy); sclerosing cholangitis; inflammation/enlargement of the submandibular, parotid, and lacrimal glands</p><p>-   <strong>Endocrine glands:</strong> Fibrosing thyroiditis, lymphocytic hypophysitis</p><p>-   <strong>Vascular:</strong> Ascending or descending aortitis (histopathologically may not be a true vasculitis)</p><p>-   <strong>Retroperitoneum:</strong> Retroperitoneal fibrosis and periaortitis</p><p>-   <strong>Renal:</strong> Tumefactive lesions occasionally mistaken for renal cell carcinoma; tubulointerstitial nephritis</p><p>-   <strong>Neuro:</strong> Pachymeningitis of the dura</p><p>•   Diagnosis:</p><p>-   Made by biopsy of involved tissue, with key findings of >30 IgG4+ plasma cells per high power field and characteristic dense lymphoplasmacytic infiltrate and “storiform” fibrosis</p><p>-   Serum IgG4 is elevated in only 70–80% of patients</p><p>•   Treatment:</p><p>-   Prednisone 0.5 mg/kg daily for 2–4 weeks, then tapered over 3–6 months</p><p>-   Mycophenolate, methotrexate, or azathioprine have been used as glucocorticoid-sparing remission-maintenance therapy, but have not been studied in clinical trials</p><p>-   Rituximab can be used for relapsed or refractory disease</p><a href=#adult-onset-stills-disease-aosd><h5 id=adult-onset-stills-disease-aosd><span class=hanchor arialabel=Anchor># </span>Adult-onset Still’s Disease (AOSD)</h5></a><p>•   Pathogenesis: Thought to be due to dysregulated innate immunity and thus it is an autoinflammatory rather than an autoimmune syndrome</p><p>•   Diagnosis and clinical features:</p><p>-   Yamaguchi Criteria for Adult-onset Still’s: See Table 9.12</p><p><strong>TABLE 9.12</strong> • Yamaguchi Criteria for Adult Onset Still’s Disease</p><p>-   Complications may include hemophagocytic lymphohistiocytosis (HLH), disseminated intravascular coagulation, and fulminant hepatitis</p><p>•   Differential diagnosis:</p><p>-    Infectious:</p><p><strong>•</strong>   Bacterial: Staphylococcal toxic shock syndrome; <em>Neisseria meningitidis</em> infection; secondary syphilis; rickettsial, anaplasma, or erlichia infection</p><p><strong>•</strong>   Viral: Acute HIV; primary VZV or rarely zoster; EBV or CMV mononucleosis; parvovirus B19; dengue; chikungunya</p><p>-   Malignant: Cutaneous lymphoma or leukemia; paraneoplastic dermatoses (pemphigus; Sweet syndrome)</p><p>-   Autoimmune: SLE, dermatomyositis, MCTD</p><p>-   Drug: DIHS (formerly DRESS); SJS/TEN</p><p>•   Treatment: DMARDs such as methotrexate are effective for arthritis; IL-1 inhibitors are effective for fevers and other manifestations</p><a href=#sarcoidosis><h5 id=sarcoidosis><span class=hanchor arialabel=Anchor># </span>Sarcoidosis</h5></a><p>•   Pathogenesis: Incompletely characterized but thought to involve dysregulated activation of CD4+ T cells and formation of granulomas (nodular collections of epithelioid macrophages) in multiple tissues</p><p>•   Clinical features:</p><p>-   <strong>Pulm</strong> (>90%): Bilateral hilar adenopathy, perilymphatic nodules, and ILD-related fibrotic changes (reticulation, honey-combing, traction bronchiectasis)</p><p>-   <strong>Ocular</strong> (20–30%): Uveitis – usually anterior but can also be posterior</p><p>-   <strong>Cutaneous</strong> (20–30%): Erythema nodosum; lupus pernio (facial rash involving violaceous plaques and nodules over the nose, nasal alae, malar areas, nasolabial folds, scalp, and hairline)</p><p>-   <strong>Articular</strong> (5%): Polyarticular (and rarely erosive) arthritis typically affecting the ankles, knees, and wrists; typically resolves in weeks to months without intervention</p><p>-   <strong>Musculoskeletal</strong>: Lytic bone lesions (10%), sarcoid myopathy (common but only symptomatic in 0.5–5% patients)</p><p>-   <strong>Cardiac</strong> (10%): Heart block/conduction system disease, ventricular arrythmias, dilated cardiomyopathy. Consider cardiac PET or cardiac MRI if suspicion for cardiac involvement.</p><p>-   <strong>Neuro:</strong> CN VII palsy most common, but CN II (optic neuritis), III, V, VIII and IX lesions can also occur. Aseptic meningitis and hypophysitis are less common manifestations.</p><p>-   <strong>Exocrine glands:</strong> Parotitis resulting in sicca symptoms</p><p>•   Sarcoidosis sub-syndromes: These syndromes obviate the need for diagnostic biopsy in most cases</p><p>-   Asymptomatic bilateral hilar adenopathy (e.g., no fevers, night sweats, weight loss to suggest malignancy)</p><p>-   Löfgren syndrome: Constellation of bilateral hilar adenopathy, erythema nodosum, migratory polyarthralgias/arthritis. 95% specific for sarcoidosis and obviates the need for biopsy</p><p>-   Heerfordt syndrome (uveoparotid fever): Fever, uveitis, parotitis +/- CN VII palsy, associated with sicca symptoms</p><p>•   Diagnosis: Biopsy of involved tissue (e.g., hilar lymph node, lung parenchyma) showing non-caseating granulomas (e.g., no central necrosis). Patients presenting with one of the sub-syndromes above may not require a biopsy unless diagnostic uncertainty is present.</p><p>•   Treatment:</p><p>-   Generally, treat disease if symptomatic but can often just monitor if asymptomatic</p><p>-   Glucocorticoids (e.g., prednisone 20mg daily) for at least 8–12 months are the first-line therapy for symptomatic pulmonary and extrapulmonary disease</p><p>-   For patients who have persistent disease activity or intolerable side effects with glucocorticoids alone:</p><p><strong>•</strong>   Methotrexate is effective for disease activity in multiple tissues</p><p><strong>•</strong>   Hydroxychloroquine and doxycycline/minocycline are effective for cutaneous disease</p><p><strong>•</strong>   TNFα inhibitors are used for patients with persistent disease activity despite non-biologic DMARD therapy</p><a href=#fibromyalgia><h5 id=fibromyalgia><span class=hanchor arialabel=Anchor># </span>Fibromyalgia</h5></a><p>•   Pathogenesis: Thought to involve inappropriately strong or persistent sensory pain signals from neurons in the dorsal root ganglia and impairment of efferent adrenergic neurons that normally dampen pain sensation, causing allodynia and “temporal summation” of pain stimuli</p><p>•   Epidemiology: Prevalence estimate 2–3% of population, F:M = 3:1</p><p>•   Diagnosis and clinical features:</p><p>-   There are multiple screening tools; one of the most simple ones is from the American Pain Society and the FDA (<em>J Pain</em> <strong>2019;20:611</strong>) and involves pain at ≥6 body sites as well as insomnia (Table 9.13)</p><p><strong>TABLE 9.13</strong> • Fibromyalgia Diagnostic Criteria (2019 AAPT*)</p><p>-   Key differential diagnostic considerations include depression, hypothyroidism, or adrenal insufficiency, which should be excluded</p><p>-   Fibromyalgia often coexists with rheumatologic disease; thus, it is important to still pursue an appropriate workup in patients with clinical symptoms suggestive of an autoimmune disease</p><p>•   Treatment:</p><p>-   Aerobic exercise in a graded fashion</p><p>-   Assess trauma history and treat co-morbid psychiatric disorders including anxiety, PTSD, substance use</p><p>-   Gabapentin, pregabalin, and TCAs may be effective for both pain and insomnia; cyclobenzaprine can be useful if muscle spasms are present</p><a href=#inherited-diseases-of-connective-tissues><h5 id=inherited-diseases-of-connective-tissues><span class=hanchor arialabel=Anchor># </span>Inherited Diseases of Connective Tissues</h5></a><p>See Table 9.14</p><p><strong>TABLE 9.14</strong> • Inherited Connective Tissue Diseases</p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/abdominal-pain/ data-ctx="Other Rheumatologic Conditions" data-src=/abdominal-pain class=internal-link>abdominal pain</a></li><li><a href=/rheumatology-diseases-pathophysiology/ data-ctx="Other Rheumatologic Conditions" data-src=/rheumatology-diseases-pathophysiology class=internal-link>rheumatology diseases & pathophysiology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>